Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes
Authors' conclusion
The TCF7L2 variant is associated with less obesity, lower insulin secretion and higher insulin action at diabetes onset, and decreased risk of cardiovascular events following type 2 diabetes onset.
Study context
- Population
- Individuals with T2D at diagnosis
- Participants
- 9,231 individuals
- Exposure
- Per rs7903146 T-allele
- Outcome
- Clinical characteristics at diabetes onset, per T-allele
- Follow-up
- Diagnosis
Methodological details10-year follow-up, per-allele analysis, adjusted for sex, calendar year at birth, age at enrollment and diabetes duration
- 10-year follow-up
- Per-allele analysis
- Adjusted for sex, calendar year at birth, age at enrollment and diabetes duration
Main finding
As reported in the abstract
Lower BMI, kg/m²
0.6
95% CI 0.4, 0.8
Smaller waist circumference, cm
1.4
95% CI 1.0, 1.8
Lower insulin secretion
5.6%
95% CI 4.2, 7.0
Higher insulin sensitivity
5.0%
95% CI 3.3, 6.7
Observational data: associations, not effects.
Further findings
Complication risk post-diagnosis, per T-allele (Cox regression) · 10 years
- MACE
- 0.87 (95% CI 0.79, 0.95)
- MI
- 0.82 (95% CI 0.72, 0.93)
- HF
- 0.85 (95% CI 0.73, 1.00)
- No significant impact on microvascular complications
Original publication
Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes. Diabetes Obes Metab. Published 8 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →